Shaina Gomez Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects roughly one-third of adults globally and carries strong associations with obesity, insulin resistance, and type 2 diabetes.¹ Rather than a simple problem of fat storage, MASLD is increasingly understood as a progressive metabolic disease shaped by dysregulated transcription, heightened de…

David Denton Background: In recent history Metabolic-Associated Steatotic Liver Disease (MASLD) has emerged as a major global health challenge, closely tied to dietary patterns and metabolic dysregulation1. Recent research highlights the distinct metabolic and molecular consequences of fructose consumption, as opposed to glucose, in promoting hepatic steatosis and systemic metabolic…

Hassan Baig Background:  Metabolic Dysfunction-Associated Steatohepatitis (MASH), previously known as NASH, the progressive inflammatory subtype of nonalcoholic fatty liver disease (NAFLD), affects up to 25% of the global population and is projected to become the leading cause of liver transplantation by 2030¹. MASH is driven by metabolic dysfunction and sustained…

Jason Wild  Background: NAFLD is an increasingly prevalent disease worldwide and costs the United States alone $100M annually2. It has recently been renamed to metabolic associated fatty liver disease (MAFLD) and defines a spectrum of liver disease that range from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH)2,3. The pathogenesis…

Ethan Hardy Background: Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), poses a significant global health challenge, affecting approximately 32.4% of the global population.1-4 Characterized by hepatic lipid accumulation and associated complications such as liver fibrosis and hepatocellular carcinoma, this condition underscores the need…